TRML VS ORGO Stock Comparison

Performance

TRML
100/100

TRML returned 56.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

ORGO
66/100

ORGO returned -11.27% in the last 12 months. Based on SPY's performance of -13.35%, its performance is above average giving it a score of 65 of 100.

Volatility

TRML
67/100

TRML has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

ORGO
42/100

ORGO has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Sentiment

TRML

"Sentiment" not found for TRML

ORGO
67/100

ORGO had a bullish sentiment score of 66.87% across Twitter and StockTwits over the last 12 months. It had an average of 3.12 posts, 0.50 comments, and 2.12 likes per day.

Technicals

TRML

"Technicals" not found for TRML

ORGO
64/100

ORGO receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

TRML

"Earnings" not found for TRML

ORGO
10/100

ORGO has missed earnings 5 times in the last 20 quarters.

Profit

TRML

"Profit" not found for TRML

ORGO
51/100

Out of the last 20 quarters, ORGO has had 12 profitable quarters and has increased their profits year over year on 6 of them.

All score calculations are broken down here to help you make more informed investing decisions

Tourmaline Bio, Inc. Common Stock Summary

Nasdaq / TRML

Healthcare

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Organogenesis Holdings Inc. Class A Common Stock Summary

Nasdaq / ORGO

Healthcare

Drug Manufacturers - Specialty & Generic

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Power up your portfolio